



Practitioner's Docket No. 55508(45487)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bjarne Due Larsen

Application No.: 09/341,590

Filed: July 12, 1999

For: PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED
TENDENCY TOWARDS ENZYMATIC HYDROLYSIS

Group No.: 1653

Examiner: Lukton, D.

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF SUBSTITUTE SPECIFICATION (37 C.F.R. SECTION 1.125)

NOTE: A substitute specification, excluding the claims, may be filed at any point up to payment of the issue fee if it is accompanied by items indicated below. See 37 C.F.R. section 1.125(b).

1. Enclosed is a substitute specification for the originally filed specification in this application.

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. SECTION 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service
with sufficient postage as first class mail in an
envelope addressed to the Commissioner for
Patents, P. O. Box 1450, Alexandria, VA 22313-
1450.

FACSIMILE

transmitted by facsimile to the Patent and
Trademark Office.


Signature

Date: **July 2, 2003**

Patricia A. Barnes
(type or print name of person certifying)

(Transmittal of Substitute Specification--page 1 of 2)

NOTE: The substitute specification must be submitted in clean form without markings as to amended material. 37 C.F.R. section 1.125(c).

2. *(complete the following applicable item)*

[X] This substitute specification is submitted, in response to a requirement by the Examiner.

OR

[] This substitute specification is being voluntarily submitted, in order to facilitate the processing of the application.

3. Also enclosed is a marked-up copy of the substitute specification showing the matter being added to and the matter being deleted from the specification.

4. Accompanying this transmittal is a statement, as required by 37 C.F.R. section 1.125, that the substitute specification transmitted herewith contains no new matter.



SIGNATURE OF PRACTITIONER

Reg. No. 40,927

Robert L. Buchanan

(type or print name of practitioner)

EDWARDS & ANGELL, LLP

P. O. Box 9169, Boston, MA 02209

P.O. Address

Tel. No.: (617) 439-4444
Fax Nos: (617) 439-4170 / 7748

Customer No.: 21874



21874

PATENT TRADEMARK OFFICE

#340537

(Transmittal of Substitute Specification--page 2 of 2)



Practitioner's Docket No. 55508(45487)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 09 2003

TECH CENTER 1600/2900

In re application of: Bjarne Due Larsen
Application No.: 09/341,590
Filed: July 12, 1999
For: PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED
TENDENCY TOWARDS ENZYMATIC HYDROLYSIS

Group No.: 1653
Examiner: Lukton, D.

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT THAT SUBSTITUTE SPECIFICATION
CONTAINS NO NEW MATTER (37 C.F.R. SECTION 1.125)**

1. Identification of person making this statement

Robert L. Buchanan
(*type or print name*)
EDWARDS & ANGELL, LLP
P. O. Box 9169, Boston, MA 02209
Address

The person making this statement is:

(*complete applicable item*)

[] the inventor in this application.

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. SECTION 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- deposited with the United States Postal Service
with sufficient postage as first class mail in an
envelope addressed to the Commissioner for
Patents, P. O. Box 1450, Alexandria, VA 22313-
1450.

FACSIMILE

- transmitted by facsimile to the Patent and
Trademark Office.

Patricia A. Barnes

Signature

Date: **July 2, 2003**

Patricia A. Barnes

(*type or print name of person certifying*)

the attorney in this application, Registration Number 40,927.
 other (*indicate relationship*)

2. Statement

I hereby state that the accompanying substitute specification contains no new matter over that contained in the above-identified application originally filed.

(complete the following, if applicable)

I further state that the changes made are the same as indicated in the inter-lined original specification also accompanying this declaration.



Signature of person making statement

#340540

(Statement that Substitute Specification Contains No New Matter--page 2 of 2)

RECEIVED

PATENT JUL 09 2003

EXCH CENTER 1600/2900



Practitioner's Docket No. 55508(45487)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bjarne Due Larsen

Application No.: 09/341,590

Group No.: 1653

Filed: July 12, 1999

Examiner: Lukton, D.

For: PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED
TENDENCY TOWARDS ENZYMATIC HYDROLYSIS

Mail Stop: Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,
AND/OR AMENDMENT PERTAINING THERETO
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail. as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office (703) _____._____._____


Signature

Date: July 2, 2003

Patricia A. Barnes

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).

"Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an

AND/OR AMINO ACID SEQUENCE

(check and complete this item, if applicable)

1. This replies to the Office Letter DATED _____.

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the application number from the return post card or the attorney's docket number added.

- A copy of the Office Letter is enclosed.

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, _____ Robert L. Buchanan
(type or print name of person signing below)

state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith is/are:

(check each item as applicable)

- A. "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application.
Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B. An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C. A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D. Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:

Application No.: 0 /

Filed:

For:

Group No.:

Examiner:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence

Identifier(s)" of the application as follows:

Computer Readable Form (other application)	"Sequence Identifier" (this application)
-----------------------------------------------	---------------------------------------------

NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference maybe made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. Section 1.821(e).

E. A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. Section 1.821(g).

Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. Section 1.821(b).

F. Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.

Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

**STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

(complete applicable item A and/or B)

A. Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.

- B. [X] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

STATUS

5. Applicant is

[X] a small entity. A statement:

[] is attached.

[X] was already filed.

[] other than a small entity.

EXTENSION OF TERM

- 6.

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).

NOTE: See 37 C.F.R. Section 1.645 for extensions of time in interference proceedings and 37 C.F.R. Section 1.550(c) for extensions of time in reexamination proceedings.

7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.

(complete (a) or (b) as applicable)

- (a) [] Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:

Extension <u>(months)</u>	Fee for other than <u>small entity</u>	Fee for <u>small entity</u>
[] one month	\$ 110.00	\$ 55.00
[] two months	\$ 410.00	\$ 205.00
[] three months	\$ 930.00	\$ 465.00
[] four months	\$1,450.00	\$ 725.00

Fee \$ _____

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

- [] An extension for _____ months has already been secured, and the fee paid therefor of \$ _____ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$ _____

OR

- (b) [] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

FEE PAYMENT

8. [] Attached is a check in the sum of \$ _____.

- [] Charge Account No. _____ the sum of \$ _____.
A duplicate of this transmittal is attached.

FEE DEFICIENCY

9.


NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.

10. If any additional extension and/or fee is required, charge Account No. 04-1105.

SIGNATURE(s)

Robert L. Buchanan

(type or print name of person signing statement)


Signature

July 2, 2003
Date
EDWARDS & ANGELL, LLP
P. O. Box 9169, Boston, MA 02209

P.O. Address of Signatory

(If applicable)

Tel. No.: (617) 439-4444

Fax Nos.: (617) 439-4170 / 7748

Customer No.: 21874



21874

PATENT TRADEMARK OFFICE

(complete the following, if applicable)

- Inventor
 Assignee of complete interest
 Person authorized to sign on behalf of assignee
 Practitioner of record
 Filed under Rule 34(a)
 Registration No. 40,927
 Other

(specify identity of person signing)

(type name of assignee)

Address of assignee

Title of person authorized to sign on behalf of assignee

A "STATEMENT UNDER 37 C.F.R. Section 3.73(b)" is attached.

Assignment recorded in PTO on _____
Reel _____ Frame _____

SIGNATURE OF PRACTITIONER

Reg. No.

(type or print name of practitioner)

Tel. No.: ()

P.O. Address

Customer No.:

#340507